痰热清注射液对急性加重期慢性阻塞性肺疾病痰热壅肺证中医症状及红细胞免疫功能的影响

目的探究痰热清注射液联合西医常规治疗急性加重期慢性阻塞性肺疾病(AECOPD)痰热壅肺证患者疗效及对中医症状、肺功能、红细胞免疫功能的影响。方法收集2016年9月-2018年8月在湖北省第三人民医院诊断为AECOPD痰热壅肺证患者130例,随机分为2组。观察组给予痰热清注射液联合西医常规治疗,对照组给予西医常规治疗,2组疗程均为14 d。治疗过程中2组各有5例脱落,每组各60例完成治疗。观察2组治疗前后中医主症评分及总症状评分、肺功能一秒用力呼气容积(FEV1)、用力肺活量(FVC)、一秒用力呼气容积占预计值百分比(FEV1%)]和红细胞免疫功能红细胞C3b受体花环(RBC-C3bR)、红细胞免疫复合物花环(RBC-ICR)、红细胞免疫调节因子的C3b受体花环促进率(RFER)和红细胞免疫调节因子的C3b受体花环抑制率(RFIR)]变化,统计2组临床疗效及不良反应发生情况。结果治疗后2组各主症评分及中医症状总评分、RBC-ICR、RFIR均明显低于治疗前(P均<0.05),且观察组治疗后均明显低于对照组(P均<0.05);治疗后2组FEV1、FEV1%、RBC-C3bR和RFER均明显高于治疗前(P均<0.05),且观察组均明显高于对照组(P均<0.05);治疗后观察组FVC较治疗前明显升高(P<0.05),但与对照组治疗后比较差异无统计学意义(P>0.05)。观察组总有效率为96.7%(58/60),对照组为80.0%(48/60),观察组总有效率明显高于对照组(P<0.05)。2组不良反应发生情况比较差异无统计学意义(P>0.05)。结论痰热清注射液联合西医常规治疗能明显改善AECOPD痰热壅肺证患者临床症状及肺功能,显著提高患者红细胞免疫功能,其疗效优于西医常规治疗。

Effects of Tanreqing injection on TCM symptoms and red blood cell immune function in patients with AECOPD of syndrome of phlegm-heat congesting in the lung

Objective It is to explore the efficacy of Tanreqing injection combined with normal western medicine in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD) with syndrome of phlegm-heat congesting in the lung and its effects on TCM symptoms, lung function, and red cell immune function. Methods A total of 130 patients diagnosed with AECOPD with syndrome of phlegm-heat congesting in the lung at the Third People’s Hospital of Hubei Province from September 2016 to August 2018 were randomly divided into two groups. The observation group was given Tanreqing injection combined with conventional western medicine treatment, and the control group was given conventional western medicine treatment. Both groups were treated for 14 days. During the course of treatment, 5 cases were lost in each of the 2 groups, and 60 cases were completed in each group. The changes in TCM main symptom score and total symptom score, lung function forced expiratory volume in one second(FEV1), forced vital capacity(FVC), forced expiratory volume in one second as a percentage of expected value(FEV1%)] and red blood cell immune function red blood cell C3 b receptor rosette(RBC-C3 bR), red blood cell immune complex rosette(RBC-ICR), red blood cell regulator factor enhance rate(RFER), and red blood cell immune adherence inhibitor factor(RFIR)] before and after treatment before and after treatment were observed, the clinical efficacy and adverse reactions of the two groups were evaluated or recorded. Results After treatment, the main symptom scores, total scores of TCM symptoms, RBC-ICR, and RFIR were significantly lower than those before treatment in in the two groups(P<0.05), and the observation group was significantly lower than the control group after treatment(P<0.05). After treatment, FEV1, FEV1%, RBC-C3 bR and RFER were significantly higher in both groups than those before treatment(P<0.05), and the observation group was significantly higher than the control group(P<0.05). FVC was increased significantly after treatment compared with that before treatment in the observation group(P<0.05), but there was no significant difference compared with the control group after treatment(P>0.05). The total effective rate in the observation group was 96.7%(58/60), and the control group was 80.0%(48/60), the rate in the observation group was significantly higher than the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion Tanreqing injection combined with conventional western medicine treatment can significantly improve the clinical symptoms and pulmonary function of patients with AECOPD of type of phlegm-heat congesting in the lung, and can significantly improve the red blood cell immune function of patients, its curative effect is better than normal western medicine.